Kura Oncology and Kyowa Kirin Announce Key Data Presentations
In an exciting announcement, Kura Oncology, Inc. (NASDAQ: KURA) and Kyowa Kirin Co., Ltd. have revealed significant details about their upcoming presentations regarding ziftomenib, a novel investigational drug, at a prominent medical meeting on December 8, 2025.
Focus on Innovative Treatment for Acute Myeloid Leukemia
The focus of these presentations is the KOMET-007 clinical trial, where ziftomenib is being studied in combination with established chemotherapy options for patients suffering from either NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML). These types of AML present unique treatment challenges, and the research aims to provide valuable insights into effective therapies.
Highlighting Clinical Trial Results
As a key component of this ongoing Phase 1a/b study, the presentations will share data from both newly diagnosed adult patients and those with relapsed or refractory AML. Ziftomenib is being assessed alongside venetoclax and azacitidine, two established chemotherapy agents. The results are expected to include updated clinical activity and safety data that could reshape how AML is treated.
Looking Forward to ASH 2025 Presentations
Presentations scheduled for ASH 2025 will reflect a more comprehensive understanding of ziftomenib's impact due to a longer patient follow-up. Dr. Mollie Leoni of Kura Oncology expressed optimism about sharing these advancements, indicating that they are part of an extensive development strategy. The goal is to explore how menin inhibition may benefit a broad spectrum of patients.
A Comprehensive Development Program
Kura’s comprehensive development program underscores its commitment to enhancing treatment options in oncology. As studies progress, including the pivotal KOMET-017 trial, Kura's findings may provide further evidence of ziftomenib's efficacy as both a standalone treatment and in combination with established therapies. This thorough approach highlights the potential for ziftomenib to significantly improve patient outcomes in AML.
Anticipating Presentation Details
The anticipated presentations at the ASH meeting will detail two key aspects:
- Ziftomenib with Venetoclax and Azacitidine in Relapsed/Refractory AML: Updated Phase 1a/b results from the KOMET-007 study. Scheduled for December 8, 2025, this session aims to provide an in-depth look at the drug's safety and effectiveness.
- Ziftomenib with Venetoclax and Azacitidine in Newly Diagnosed AML: Further results from the same study focusing on newly diagnosed patients. Attendees can expect insights into the preliminary findings from this critical clinical trial.
About Kura Oncology
Kura Oncology is a pioneering biopharmaceutical company dedicated to advancing precision medicines for cancer treatment. Their innovative pipeline is designed to target specific cancer pathways, addressing critical needs in hematologic malignancies and solid tumors. By developing ziftomenib, they aim to confront the genetic drivers of acute myeloid leukemia while exploring broader applications of menin inhibition and other therapeutic strategies.
About Kyowa Kirin
Kyowa Kirin is a global specialty pharmaceutical company committed to developing transformative therapeutics. With over 70 years of experience, they have a strong focus on creating novel antibody-based therapies and cell and gene treatments for patients with significant unmet medical needs. Their efforts extend across various therapeutic areas, aiming to foster advancements that can truly change lives.
Frequently Asked Questions
1. What is ziftomenib?
Ziftomenib is an investigational menin inhibitor being evaluated in clinical trials for the treatment of specific genetic forms of acute myeloid leukemia.
2. What are the main findings from the KOMET-007 trial?
The KOMET-007 trial aims to assess the effectiveness and safety of ziftomenib in combination with standard chemotherapy agents like venetoclax and azacitidine.
3. When will the presentations take place?
The presentations are scheduled for December 8, 2025, at the American Society of Hematology (ASH) Annual Meeting.
4. Who are the companies involved?
Kura Oncology and Kyowa Kirin are the two companies collaborating on the development and evaluation of ziftomenib for AML treatment.
5. How can I learn more about the results?
Results will be shared during the presentations at ASH 2025, and additional information will be available on Kura's official website after the event.
